Company news
Instil Bio, Inc. news in 2022
Instil Bio, Inc.'s news releases, calls and decks from 2022, newest first.
Instil Bio Announces Prioritization of Genetically Engineered CoStAR-TIL Program with ITIL-306 in Advanced Solid Tumors and Reduction in Workforce
December 7, 2022
Instil Bio Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 13, 2022
Instil Bio Announces Poster Presentations of CoStAR Platform at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 7, 2022
Instil Bio Announces Voluntary Pause of Enrollment in Ongoing Clinical Trials Related to Manufacturing
October 30, 2022
Instil Bio Announces First Patient Dosed with ITIL-306, our First Engineered TIL Therapy Using the CoStAR Platform Targeting Folate Receptor Alpha (FRα), in Non-Small Cell Lung Cancer
October 17, 2022
Instil Bio Announces Appointment of Tim Moore as Chief Operating Officer
September 5, 2022
Instil Bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 11, 2022
Instil Bio Announces IND Clearance of First CoStAR-TIL program, ITIL-306, Designed to Enhance Activity in the Tumor Microenvironment
May 26, 2022
Instil Bio Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 15, 2022
Instil Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
March 6, 2022